Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-B2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes

Oncogene

Volumn 28, Issue 13, 2009, Pages 1626-1638

  Robert, I ^a   Aussems, M ^a   Keutgens, A ^a   Zhang, X ^a   Hennuy, B ^a   Viatour, P ^a   Vanstraelen, G ^a   Merville, M P ^a   Chapelle, J P ^a   De Leval, L ^a,b   Lambert, F ^a   Dejardin, E ^a   Gothot, A ^a   Chariot, A ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

H3K4 HMT; MMP9; NF B; P100

Indexed keywords

GELATINASE B; HISTONE METHYLTRANSFERASE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN 2; MIXED LINEAGE LEUKEMIA PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN 1; MIXED LINEAGE LEUKEMIA PROTEIN 2; PROTEIN H3K4; PROTEIN P100; PROTEIN P52; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL INTERACTION; CHROMATIN; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST; GENE INDUCTION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LYMPHOMA CELL; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELLS, CULTURED; DNA-BINDING PROTEINS; ENZYME INDUCTION; HELA CELLS; HUMANS; LYSINE; MATRIX METALLOPROTEINASE 9; MICE; MOLECULAR SEQUENCE DATA; MULTIPROTEIN COMPLEXES; MUTANT PROTEINS; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM PROTEINS; NF-KAPPA B P52 SUBUNIT; NIH 3T3 CELLS; ONCOGENE PROTEINS, FUSION; PROTEIN METHYLTRANSFERASES; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 64049112779     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.6     Document Type: Article

References (61)

1. Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T et al. (2007). New nomenclature for chromatin-modifying enzymes. Cell 131: 633-636.
2. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. (2007). Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130.
3. Aoudjit F, Potworowski EF, St-Pierre Y. (1998). The metastatic characteristics of murine lymphoma cell lines in vivo are manifested after target organ invasion. Blood 91: 623-629.
4. Aygun O, Svejstrup J, Liu Y. (2008). A RECQ5-RNA polymerase II association identified by targeted proteomic analysis of human chromatin. Proc Natl Acad Sci USA 105: 8580-8584.
5. Berger SL. (2007). The complex language of chromatin regulation during transcription. Nature 447: 407-412.
6. Bhaumik SR, Smith E, Shilatifard A. (2007). Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 14: 1008-1016.
7. Bonizzi G, Karin M. (2004). The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280-288.
8. Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K et al. (1993). The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 72: 729-739.
9. Briggs SD, Bryk M, StrahlBD, Cheung WL, Davie JK, Dent SY et al. (2001). Histone H3 lysine 4 methylation is mediated by Set1 and required for cell growth and rDNA silencing in Saccharomyces cerevisiae. Genes Dev 15: 3286-3295.
10. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. (1999). Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 18: 3063-3070.
11. Chang CC, Zhang J, Lombardi L, Neri A, Dalla-Favera R. (1995). Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators. Mol Cell Biol 15: 5180-5187.
12. Claudio E, Brown K, Park S, Wang H, Siebenlist U. (2002). BAFFinduced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 3: 958-965.
13. Coope HJ, Atkinson PG, Huhse B, Belich M, Janzen J, Holman MJ et al. (2002). CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 21: 5375-5385.
14. Courtois G, Gilmore TD. (2006). Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 25: 6831-6843.
15. De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G, Natoli G. (2007). The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 130: 1083-1094.
16. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C et al. (2002). The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17: 525-535.
17. Derudder E, Laferte A, Ferreira V, MishalZ, Baud V, Tarantino N et al. (2003). Identification and characterization of p100HB, a new mutant form of p100/NF-kappa B2. Biochem Biophys Res Commun 308: 744-749.
18. Emmerich F, Meiser M, HummelM, DemelG, Foss HD, Jundt F et al. (1999). Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 94: 3129-3134.
19. Epinat JC, Kazandjian D, Harkness DD, Petros S, Dave J, White DW et al. (2000). Mutant envelope residues confer a transactivation function onto N-terminalsequence s of the v-Reloncoprotein. Oncogene 19: 599-607.
20. Fracchiolla NS, Lombardi L, Salina M, Migliazza A, Baldini L, Berti E et al. (1993). Structuralal terations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies. Oncogene 8: 2839-2845.
21. Glaser S, Schaft J, Lubitz S, Vintersten K, van der Hoeven F, Tufteland KR et al. (2006). Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development. Development 133: 1423-1432.
22. Hayden MS, Ghosh S. (2008). Shared principles in NF-kappaB signaling. Cell 132: 344-362.
23. Heissig B, Hattori K, Friedrich M, Rafii S, Werb Z. (2003). Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases. Curr Opin Hematol 10: 136-141.
24. Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC et al. (2004). Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell 13: 587-597.
25. Ishikawa H, Carrasco D, Claudio E, Ryseck RP, Bravo R. (1997). Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-kappaB2. J Exp Med 186: 999-1014.
26. Jost PJ, Ruland J. (2007). Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109: 2700-2707.
27. JungnickelB, Staratschek-Jox A, Brauninger A, Spieker T, Wolf J, DiehlV et al. (2000). Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 191: 395-402.
28. Karin M, Lin A. (2002). NF-kappaB at the crossroads of life and death. Nat Immunol 3: 221-227.
29. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. (2007). Promiscuous mutations activate the noncanonicalNFkappaB pathway in multiple myeloma. Cancer Cell 12: 131-144.
30. Keutgens A, Robert I, Viatour P, Chariot A. (2006). Deregulated NFkappaB activity in haematological malignancies. Biochem Pharmacol 72: 1069-1080.
31. Kim KE, Gu C, Thakur S, Vieira E, Lin JC, Rabson AB. (2000). Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes. Oncogene 19: 1334-1345.
32. Klose RJ, Kallin EM, Zhang Y. (2006). JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet 7: 715-727.
33. Klose RJ, Yan Q, Tothova Z, Yamane K, Erdjument-Bromage H, Tempst P et al. (2007). The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell 128: 889-900.
34. Kouskouti A, Talianidis I. (2005). Histone modifications defining active genes persist after transcriptionaland mitotic inactivation. EMBO J 24: 347-357.
35. Lalancette M, Aoudjit F, Potworowski EF, St-Pierre Y. (2000). Resistance of ICAM-1-deficient mice to metastasis overcome by increased aggressiveness of lymphoma cells. Blood 95: 314-319.
36. Li Q, Verma IM. (2002). NF-kappaB regulation in the immune system. Nat Rev Immunol 2: 725-734.
37. McKeithan TW, Rowley JD, Shows TB, Diaz MO. (1987). Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 84: 9257-9260.
38. Miller T, Krogan NJ, Dover J, Erdjument-Bromage H, Tempst P, Johnston M et al. (2001). COMPASS: a complex of proteins associated with a trithorax-related SET domain protein. Proc Natl Acad Sci USA 98: 12902-12907.
39. Mori N, Sato H, Hayashibara T, Senba M, Hayashi T, Yamada Y et al. (2002). Human T-cell leukemia virus type I Tax transactivates the matrix metalloproteinase-9 gene: potential role in mediating adult T-cell leukemia invasiveness. Blood 99: 1341-1349.
40. Nagy PL, Griesenbeck J, Kornberg RD, Cleary ML. (2002). A trithorax-group complex purified from Saccharomyces cerevisiae is required for methylation of histone H3. Proc Natl Acad Sci USA 99: 90-94.
41. Neri A, Chang CC, Lombardi L, Salina M, Corradini P, Maiolo AT et al. (1991). B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell 67: 1075-1087.
42. Noma K, Grewal SI. (2002). Histone H3 lysine 4 methylation is mediated by Set1 and promotes maintenance of active chromatin states in fission yeast. Proc Natl Acad Sci USA 99(Suppl 4): 16438-16445.
43. Perkins ND. (2007). Integrating cell-signalling pathways with NFkappaB and IKK function. Nat Rev Mol Cell Biol 8: 49-62.
44. Qing G, Qu Z, Xiao G. (2007). Endoproteolytic processing of Cterminally truncated NF-kappaB2 precursors at kappa B-containing promoters. Proc Natl Acad Sci USA 104: 5324-5329.
45. Redondo-Munoz J, Escobar-Diaz E, Samaniego R, Terol MJ, Garcia-Marco JA, Garcia-Pardo A. (2006). MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 108: 3143-3151.
46. Ruthenburg AJ, Allis CD, Wysocka J. (2007). Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell 25: 15-30.
47. Saitoh Y, Yamamoto N, Dewan MZ, Sugimoto H, Martinez Bruyn VJ, Iwasaki Y et al. (2008). Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. Blood 111: 5118-5129.
48. Sakata K, Satoh M, Someya M, Asanuma H, Nagakura H, Oouchi A et al. (2004). Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer 100: 356-365.
49. Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, Emre NC et al. (2002). Active genes are tri-methylated at K4 of histone H3. Nature 419: 407-411.
50. Shilatifard A. (2006). Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu Rev Biochem 75: 243-269.
51. Shim JH, Xiao C, PaschalAE, Bailey ST, Rao P, Hayden MS et al. (2005). TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 19: 2668-2681.
52. Siebenlist U, Brown K, Claudio E. (2005). Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol 5: 435-445.
53. Srivastava AK, Qin X, Wedhas N, Arnush M, Linkhart TA, Chadwick RB et al. (2007). Tumor necrosis factor-alpha augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-beta-activated kinase 1 (TAK1)-dependent signaling pathway. J Biol Chem 282: 35113-35124.
54. Thakur S, Lin HC, Tseng WT, Kumar S, Bravo R, Foss F et al. (1994). Rearrangement and altered expression of the NFKB-2 gene in human cutaneous T-lymphoma cells. Oncogene 9: 2335-2344.
55. Viatour P, Dejardin E, Warnier M, Lair F, Claudio E, Bureau F et al. (2004). GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell 16: 35-45.
56. Viatour P, Legrand-Poels S, van Lint C, Warnier M, Merville MP, Gielen J et al. (2003). Cytoplasmic IkappaBalpha increases NFkappaB-independent transcription through binding to histone deacetylase (HDAC) 1 and HDAC3. J Biol Chem 278: 46541-46548.
57. Wang Z, Zhang B, Yang L, Ding J, Ding HF. (2008). Constitutive production of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression. J Biol Chem 283: 10698-10706.
58. Xiao G, Harhaj EW, Sun SC. (2001). NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 7: 401-409.
59. Yoshizaki T, Sato H, Furukawa M, Pagano JS. (1998). The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci USA 95: 3621-3626.
60. Zhang B, Wang Z, Li T, Tsitsikov EN, Ding HF. (2007). NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis. Blood 110: 743-751.
61. Zhang J, Chang CC, Lombardi L, Dalla-Favera R. (1994). Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions. Oncogene 9: 1931-1937.